Development of pluripotent stem cells for vascular therapy

Vascular Pharmacology

Volumn 56, Issue 5-6, 2012, Pages 288-296

  Volz, Katharina S ^a   Miljan, Erik ^b   Khoo, Amanda ^a   Cooke, John P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Simply Cells Ltd   (United Kingdom)

Author keywords

Angiogenesis; Nuclear reprogramming; Peripheral arterial disease; Regeneration; Regenerative medicine

Indexed keywords

ADULT STEM CELL; CELL DIFFERENTIATION; CELL REGENERATION; CELLULAR DISTRIBUTION; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; GOOD MANUFACTURING PRACTICE; HUMAN; NUCLEAR REPROGRAMMING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TISSUE SURVIVAL; ANIMAL; METHODOLOGY; PATHOPHYSIOLOGY; REGENERATION; REGENERATIVE MEDICINE; TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PERIPHERAL ARTERIAL DISEASE; REGENERATION; REGENERATIVE MEDICINE;

EID: 84866152590     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.02.010     Document Type: Review

References (73)

1. Aasen T., Raya A., Barrero M.J., Garreta E., Consiglio A., Gonzalez F., Vassena R., Bilic J., Pekarik V., Tiscornia G., et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 2008, 26:1276-1284.
2. Aicher A., Rentsch M., Sasaki K.-I., Ellwart J.W., Fändrich F., Siebert R., Cooke J.P., Dimmeler S., Heeschen C. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ. Res. 2007, 100:581-589.
3. Anokye-Danso F., Trivedi C.M., Juhr D., Gupta M., Cui Z., Tian Y., Zhang Y., Yang W., Gruber P.J., Epstein J.A., et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011, 8:376-388.
4. Asahara T., Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am. J. Physiol. Cell Physiol. 2004, 287:C572-C579.
5. Bishop E.T., Bell G.T., Bloor S., Broom I.J., Hendry N.F., Wheatley D.N. An in vitro model of angiogenesis: basic features. Angiogenesis 1999, 3:335-344.
6. Blum B., Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv. Cancer Res. 2008, 100:133-158.
7. Blum B., Benvenisty N. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle 2009, 8:3822-3830.
8. Brafman D.A., Chang C.W., Fernandez A., Willert K., Varghese S., Chien S. Long-term human pluripotent stem cell self-renewal on synthetic polymer surfaces. Biomaterials 2010, 31:9135-9144.
9. Cho S.W., Moon S.H., Lee S.H., Kang S.W., Kim J., Lim J.M., Kim H.S., Kim B.S., Chung H.M. Improvement of postnatal neovascularization by human embryonic stem cell derived endothelial-like cell transplantation in a mouse model of hindlimb ischemia. Circulation 2007, 116:2409-2419.
10. Dawson E., Mapili G., Erickson K., Taqvi S., Roy K. Biomaterials for stem cell differentiation. Adv. Drug Deliv. Rev. 2008, 60:215-228.
11. Derda R., Musah S., Orner B.P., Klim J.R., Li L., Kiessling L.L. High-throughput discovery of synthetic surfaces that support proliferation of pluripotent cells. J. Am. Chem. Soc. 2010, 132:1289-1295.
12. Desponts C., Ding S. Using small molecules to improve generation of induced pluripotent stem cells from somatic cells. Methods Mol. Biol. 2010, 636:207-218.
13. Dimmeler S., Burchfield J., Zeiher A.M. Cell-based therapy of myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2008, 28:208-216.
14. Donovan D., Brown N.J., Bishop E.T., Lewis C.E. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 2001, 4:113-121.
15. Fu R.H., Wang Y.C., Liu S.P., Huang C.M., Kang Y.H., Tsai C.H., Shyu W.C., Lin S.Z. Differentiation of stem cells: strategies for modifying surface biomaterials. Cell Transplant. 2010, 20:37-47.
16. Gilbert P.M., Havenstrite K.L., Magnusson K.E., Sacco A., Leonardi N.A., Kraft P., Nguyen N.K., Thrun S., Lutolf M.P., Blau H.M. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 2010, 329:1078-1081.
17. Hanna J.H., Saha K., Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010, 143:508-525.
18. Hirschi K.K., Ingram D.A., Yoder M.C. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1584-1595.
19. Huang N.F., Niiyama H., Peter C., De A., Natkunam Y., Fleissner F., Li Z., Rollins M.D., Wu J.C., Gambhir S.S., et al. Embryonic stem cell-derived endothelial cells engraft into the ischemic hindlimb and restore perfusion. Arterioscler. Thromb. Vasc. Biol. 2010, 30:984-991.
20. Huang N.F., Patlolla B., Abilez O., Sharma H., Rajadas J., Beygui R.E., Zarins C.K., Cooke J.P. A matrix micropatterning platform for cell localization and stem cell fate determination. Acta Biomater. 2010, 6:4614-4621.
21. Kaji K., Norrby K., Paca A., Mileikovsky M., Mohseni P., Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009, 458:771-775.
22. Kane N.M., Meloni M., Spencer H.L., Craig M.A., Strehl R., Milligan G., Houslay M.D., Mountford J.C., Emanueli C., Baker A.H. Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1389-1397.
23. Kim D., Kim C.H., Moon J.I., Chung Y.G., Chang M.Y., Han B.S., Ko S., Yang E., Cha K.Y., Lanza R., et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4:472-476.
24. Klim J.R., Li L., Wrighton P.J., Piekarczyk M.S., Kiessling L.L. A defined glycosaminoglycan-binding substratum for human pluripotent stem cells. Nat. Methods 2010, 7:989-994.
25. Kooreman N.G., Wu J.C. Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging. J. R. Soc. Interface 2010, 7(Suppl. 6):S753-S763.
26. Lee A.S., Tang C., Cao F., Xie X., van der Bogt K., Hwang A., Connolly A.J., Robbins R.C., Wu J.C. Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle 2009, 8:2608-2612.
27. Leeper N.J., Hunter A.L., Cooke J.P. Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent stem cells. Circulation 2010, 122:517-526.
28. Li Z., Wu J.C., Sheikh A.Y., Kraft D., Cao F., Xie X., Patel M., Gambhir S.S., Robbins R.C., Cooke J.P. Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation 2007, 116:I46-I54.
29. Li W., Wei W., Zhu S., Zhu J., Shi Y., Lin T., Hao E., Hayek A., Deng H., Ding S. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009, 4:16-19.
30. Lin T., Ambasudhan R., Yuan X., Li W., Hilcove S., Abujarour R., Lin X., Hahm H.S., Hao E., Hayek A., et al. A chemical platform for improved induction of human iPSCs. Nat. Methods 2009, 6:805-808.
31. Lutolf M.P., Gilbert P.M., Blau H.M. Designing materials to direct stem-cell fate. Nature 2009, 462:433-441.
32. Machida K., Suemizu H., Kawai K., Ishikawa T., Sawada R., Ohnishi Y., Tsuchiya T. Higher susceptibility of NOG mice to xenotransplanted tumors. J. Toxicol. Sci. 2009, 34:123-127.
33. Masip M., Veiga A., Izpisua Belmonte J.C., Simon C. Reprogramming with defined factors: from induced pluripotency to induced transdifferentiation. Mol. Hum. Reprod. 2010, 16:856-868.
34. McDevitt T.C., Palecek S.P. Innovation in the culture and derivation of pluripotent human stem cells. Curr. Opin. Biotechnol. 2008, 19:527-533.
35. Moon S.H., Kim J.S., Park S.J., Lee H.J., Do J.T., Chung H.M. A system for treating ischemic disease using human embryonic stem cell-derived endothelial cells without direct incorporation. Biomaterials 2011, 32:6445-6455.
36. Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., Okita K., Mochiduki Y., Takizawa N., Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 2008, 26:101-106.
37. Nicholas C.R., Kriegstein A.R. Regenerative medicine: cell reprogramming gets direct. Nature 2010, 463:1031-1032.
38. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
39. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
40. Onodera R., Teramukai S., Tanaka S., Kojima S., Horie T., Matoba S., Murohara T., Matsubara H., Fukushima M. Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis. Bone Marrow Transplant. 2011, 46:278-284.
41. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., Lerou P.H., Lensch M.W., Daley G.Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
42. Rufaihah A.J., Huang N.F., Jame S., Lee J.C., Nguyen H.N., Byers B., De A., Okogbaa J., Rollins M., Reijo-Pera R., et al. Endothelial cells derived from human iPSCS increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Arterioscler. Thromb. Vasc. Biol. 2011, 31:e72-e79.
43. Serra M., Brito C., Sousa M.F., Jensen J., Tostoes R., Clemente J., Strehl R., Hyllner J., Carrondo M.J., Alves P.M. Improving expansion of pluripotent human embryonic stem cells in perfused bioreactors through oxygen control. J. Biotechnol. 2010, 148:208-215.
44. Shi Y., Desponts C., Do J.T., Hahm H.S., Scholer H.R., Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008, 3:568-574.
45. Si-Tayeb K., Noto F.K., Sepac A., Sedlic F., Bosnjak Z.J., Lough J.W., Duncan S.A. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev. Biol. 2010, 10:81.
46. Sone M., Itoh H., Yamahara K., Yamashita J.K., Yurugi-Kobayashi T., Nonoguchi A., Suzuki Y., Chao T.H., Sawada N., Fukunaga Y., et al. Pathway for differentiation of human embryonic stem cells to vascular cell components and their potential for vascular regeneration. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2127-2134.
47. Stadtfeld M., Nagaya M., Utikal J., Weir G., Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322:945-949.
48. Szabo E., Rampalli S., Risueno R.M., Schnerch A., Mitchell R., Fiebig-Comyn A., Levadoux-Martin M., Bhatia M. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010, 468:521-526.
49. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
50. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
51. Tang C., Lee A.S., Volkmer J.P., Sahoo D., Nag D., Mosley A.R., Inlay M.A., Ardehali R., Chavez S.L., Pera R.R., et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat. Biotechnol. 2011, 29:829-834.
52. Tateishi-Yuyama E., Matsubara H., Murohara T., Ikeda U., Shintani S., Masaki H., Amano K., Kishimoto Y., Yoshimoto K., Akashi H., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002, 360:427-435.
53. Taura D., Sone M., Homma K., Oyamada N., Takahashi K., Tamura N., Yamanaka S., Nakao K. Induction and isolation of vascular cells from human induced pluripotent stem cells-brief report. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1100-1103.
54. Thomas R.J., Anderson D., Chandra A., Smith N.M., Young L.E., Williams D., Denning C. Automated, scalable culture of human embryonic stem cells in feeder-free conditions. Biotechnol. Bioeng. 2009, 102:1636-1644.
55. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., Manolescu A., Thorleifsson G., Stefansson H., Ingason A., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452:638-642.
56. Vasa M., Fichtlscherer S., Aicher A., Adler K., Urbich C., Martin H., Zeiher A.M., Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 2001, 89:E1-E7.
57. Vierbuchen T., Ostermeier A., Pang Z.P., Kokubu Y., Sudhof T.C., Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463:1035-1041.
58. Wang W., Yang J., Liu H., Lu D., Chen X., Zenonos Z., Campos L.S., Rad R., Guo G., Zhang S., et al. Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:18283-18288.
59. Warren L., Manos P.D., Ahfeldt T., Loh Y.H., Li H., Lau F., Ebina W., Mandal P.K., Smith Z.D., Meissner A., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
60. Wernig M., Meissner A., Cassady J.P., Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2008, 2:10-12.
61. Wilson, A.M., Sadrzadeh-Rafie, A.H., Myers, J., Assimes, T., Nead, K.T., Higgins, M., Gabriel, A., Olin, J., Cooke, J.P., 2011. Low lifetime recreational activity is a risk factor for peripheral arterial disease. J. Vasc. Surg. 54, 427-432, 432 e421-424.
62. Woltjen K., Michael I.P., Mohseni P., Desai R., Mileikovsky M., Hamalainen R., Cowling R., Wang W., Liu P., Gertsenstein M., et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009, 458:766-770.
63. Xie X., Sun A., Huang Z., Zhu W., Wang S., Zou Y., Ge J. Another possible cell source for cardiac regenerative medicine: reprogramming adult fibroblasts to cardiomyocytes and endothelial progenitor cells. Med. Hypotheses 2010, 76:365-367.
64. Xu Y., Shi Y., Ding S. A chemical approach to stem-cell biology and regenerative medicine. Nature 2008, 453:338-344.
65. Yakubov E., Rechavi G., Rozenblatt S., Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem. Biophys. Res. Commun. 2010, 394:189-193.
66. Yamashita T., Kawai H., Tian F., Ohta Y., Abe K. Tumorigenic development of induced pluripotent stem cells in ischemic mouse brain. Cell Transplant. 2010, 20:883-891.
67. Yang W.C., Patel K.G., Lee J., Ghebremariam Y.T., Wong H.E., Cooke J.P., Swartz J.R. Cell-free production of transducible transcription factors for nuclear reprogramming. Biotechnol. Bioeng. 2009, 104:1047-1058.
68. Yu J., Thomson J.A. Pluripotent stem cell lines. Genes Dev. 2008, 22:1987-1997.
69. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
70. Yu J., Hu K., Smuga-Otto K., Tian S., Stewart R., Slukvin I.I., Thomson J.A. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324:797-801.
71. Zhou W., Freed C.R. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 2009, 27:2667-2674.
72. Zhou H., Wu S., Joo J.Y., Zhu S., Han D.W., Lin T., Trauger S., Bien G., Yao S., Zhu Y., et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4:381-384.
73. Zwi-Dantsis L., Mizrahi I., Arbel G., Gepstein A., Gepstein L. Scalable production of cardiomyocytes derived from c-Myc free induced pluripotent stem cells. Tissue Eng. Part A 2010, 17:1027-1037.